Brought to you by 
Genentech gets NA rights to Altus' ALTU238
08 Jun 2021
Executive Summary
Genentech has licensed exclusive North American development, manufacturing, and marketing rights to Altus Pharmaceuticals' (oral and injectable therapeutics for gastrointestinal and metabolic conditions) ALTU238. The Phase II compound is a hormone that is subcutaneously administered once a week to patients suffering from growth hormone deficiencies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech gets NA rights to Altus' ALTU238
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice